2. What is the problem?
715,000 cases/day
While companies were working
on a rapid antigen test, COVID-19
infections were running wild
https://ourworldindata.org/covid-cases
3. What is the problem?
https://ourworldindata.org/covid-cases
SARS-CoV2
Genome
Sequenced
Deployment
of Rapid Ab
Test
While companies were working
on a rapid antigen test, COVID-19
infections were running wild
7 Month Development Time
4. What is the problem?
https://ourworldindata.org/covid-cases
Nucleotide-Based
Diagnostic
SARS-CoV2
Genome
Sequenced
1 Month Development Time
5. How does product/service solve problem?
Faster to develop
Simpler to use
Adaptable to new viruses
capture
reporter
Our Test Is:
6. What is the market use?
Highly demanded during new
infectious diseases
Absent from the market
Minimal competition
Early diagnostic test kits are:
7. What is the market use?
Highly demanded during new
infectious diseases
Absent from the market
Minimal competition
or
or
Early diagnostic test kits are:
Alternative Market Applications:
wide-market utility in research
labs
8. What competition exists?
• Antigen tests are the
gold standard for viral
testing (Abbott Labs,
etc.)
• However these take
months (~7) to develop
• RT-PCR testing is the
first viable testing done
for emerging diseases
• Results take days-to-
one week to return
• In the meantime…
9. What is the status of the intellectual property?
• Patent pending on Nucleotide-Based
Infectious Disease Diagnostic Test
• Patents in preparation:
– Nucleotide-Based Reporter Adaptors
– Amplification Reagent for Immunoassays
10. What is the stage of development?
-0.4
-0.2
0
0.2
0.4
0.6
0.8
1
1.2
1.4
positive
control
scrambled
target
negative
control
100nM 10nM 1nM 100pM
OD370
LOD for oligonucleotide ELISA
Early proof of principle tests
have been successful
Methods will be developed
for sample processing and
detection of physiological
concentrations of virus
11. What is needed for further development?
• Business Partner (CEO)
• Support for Preclinical
Development
• Clinical Connection for
Final Validation
• Equipment and
Consumables
• Scaling to Production
Notes de l'éditeur
We were caught flat-footed by COVID-19. Even when we identified the organism causing the disease and sequenced its genome, we were still unable to engage a rapid testing regimen to do effective monitoring and contact tracing.
This led to the uncontrolled spread of disease across the globe
We were caught flat-footed by COVID-19. Even when we identified the organism causing the disease and sequenced its genome, we were still unable to engage a rapid testing regimen to do effective monitoring and contact tracing.
This led to the uncontrolled spread of disease across the globe
We were caught flat-footed by COVID-19. Even when we identified the organism causing the disease and sequenced its genome, we were still unable to engage a rapid testing regimen to do effective monitoring and contact tracing.
This led to the uncontrolled spread of disease across the globe
In addition to faster deployment, our nucleotide-based test would be easier to use, require less training, less equipment, and have faster turn-around time between test and result.
The COVID-19 diagnostic is just an example of an adaptive test capable of being used for numerous emerging infectious diseases. Furthermore, the development of this diagnostic has led to the invention of several related reagent types which could be used in numerous laboratory applications including Flow Cytometry, Western Blotting, and ELISAs.
The COVID-19 diagnostic is just an example of an adaptive test capable of being used for numerous emerging infectious diseases. Furthermore, the development of this diagnostic has led to the invention of several related reagent types which could be used in numerous laboratory applications including Flow Cytometry, Western Blotting, and ELISAs.
There is competition for this diagnostic. However, early-adaptable tests tend to take longer times and greater costs to process samples and provide results. Rapid, simple tests like the antibody test take many months to develop. This results in a window of opportunity for a simple, rapid test that can be developed early in an epidemic.
A provisional patent has been filed for the diagnostic test, while we are developing data to support additional applications for related products.
We have currently generated proof of principle data showing that both the concepts for the diagnostic test and the reagent labeling technology work well. Further development is required in developing the amplification reagent required to detect smaller concentrations of material as found in physiological samples. We are